{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:45:48Z","timestamp":1779183948329,"version":"3.51.4"},"reference-count":31,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2011,12,1]]},"DOI":"10.1188\/11.cjon.660-667","type":"journal-article","created":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T21:48:23Z","timestamp":1322516903000},"page":"660-667","source":"Crossref","is-referenced-by-count":9,"title":["Identification of Side Effects Associated With Intolerance to BCR-ABL Inhibitors in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1188","volume":"15","author":[{"given":"Mary Beth","family":"Rios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Ault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2011,11,26]]},"reference":[{"issue":"1","key":"1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.12.007","article-title":"The biology of chronic myelogenous leukemia: Implications for imatinib therapy","volume":"44","author":"R. Alvarez","year":"2007","journal-title":"Seminars in Hematology"},{"key":"2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"E. Atallah","year":"2007","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1188\/07.CJON.125-129","article-title":"Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia","volume":"11","author":"P. Ault","year":"2007","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1745-7599.2003.tb01310.x","article-title":"Management of molecular-targeted therapy for chronic myelogenous leukemia","volume":"15","author":"P. Ault","year":"2003","journal-title":"Journal of the American Academy of Nurse Practitioners"},{"key":"5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case series","volume":"176","author":"A. Bergeron","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"6","unstructured":"Bristol-Myers Squibb. (2010). <i>Sprycel\u00ae (dasatinib)<\/i> [Prescribing information]. Princeton, NJ: Author."},{"key":"7","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"J. Cortes","year":"2007","journal-title":"Blood"},{"key":"8","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"J. Cortes","year":"2011","journal-title":"Blood"},{"key":"9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1188\/05.CJON.535-538","article-title":"Chronic myelogenous leukemia","volume":"9","author":"J. D'Antonio","year":"2005","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1188\/09.CJON.329-335","article-title":"Practical management of dasatinib for maximum patient benefit","volume":"13","author":"I. Galinsky","year":"2009","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1634\/theonc ologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"F. Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"12","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"F. Guilhot","year":"2007","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"A. Hochhaus","year":"2007","journal-title":"Blood"},{"key":"14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.10 16\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"L. Kaminsky","year":"1997","journal-title":"Pharmacology and Therapeutics"},{"key":"15","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H. Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood.V114.22.1129.1129","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes","volume":"114","author":"H. Kantarjian","year":"2009","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"H. Kantarjian","year":"2007","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"R. Kerkel\u00e4","year":"2006","journal-title":"Nature Medicine"},{"key":"19","unstructured":"Khoury, H. J., Goldberg, S. L., Mauro, M. J., Stone, R. M., Matloub, Y., Chen T., & Guihot, F. (2008). Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: A retrospective analysis of safety [Abstract 7015]. Retrieved from <a target=\"_blank\" href='http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34779'>http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34779<\/a>"},{"key":"20","unstructured":"National Comprehensive Cancer Network. (2010). <i>NCCN Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia<\/i> [v.2.2010]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"21","unstructured":"Novartis Pharmaceuticals. (2009). <i>Gleevec\u00ae (imatinib)<\/i> [Prescribing information]. East Hanover, NJ: Author."},{"key":"22","unstructured":"Novartis Pharmaceuticals. (2010). <i>Tasigna\u00ae (nilotinib)<\/i> [Prescribing information]. East Hanover, NJ: Author."},{"key":"23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"S. O'Brien","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"24","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1002\/cncr.24432","article-title":"Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure","volume":"115","author":"A. Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"A. Quint\u00e1s-Cardama","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"26","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy","volume":"115","author":"A. Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"27","unstructured":"Rousselot, P., Bergeron, A., R\u00e9a, D., Levy, V., Picard, C., Meignin, V., \u2026 Rousselot, P. (2007). Pleural and pulmonary events in patients treated with dasatinib for chronic myeloid leukemia in chronic phase [Abstract 0546]. Retrieved from <a target=\"_blank\" href='http:\/\/online.haematologica.org\/eha12\/browserecord.php?-action=browse&-recid=546'>http:\/\/online.haematologica.org\/eha12\/browserecord.php?-action=browse&-recid=546<\/a>"},{"key":"28","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa091 2614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G. Saglio","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"29","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"N. Shah","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib","volume":"95","author":"N. Shah","year":"2010","journal-title":"Haematologica"},{"key":"31","unstructured":"Yin, O., Gallagher, N. J., Fischer, D., Zhao, L., Zhou, W., Golor, G., & Schran, H. (2009). Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin. Retrieved from <a target=\"_blank\" href='http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31547'>http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31547<\/a>"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/B213444261G13186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:13Z","timestamp":1763754493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/15\/6\/identification-side-effects-associated-intolerance-bcr-abl"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,26]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12,1]]}},"alternative-id":["B213444261G13186"],"URL":"https:\/\/doi.org\/10.1188\/11.cjon.660-667","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,26]]}}}